FDA Approves Datroway as First-Line Therapy for Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo’s Datroway offers an unprecedented improvement in survival to a patient population with no treatment options beyond chemotherapy. The post FDA Approves Datroway as First-Line Therapy for Triple-Negative Breast Cancer appeared first on Inside Precision Medicine .